Delayed hematopoietic reconstitution after cord blood (CB) transplantation (CBT) needs to be overcome. Bone marrow-derived mesenchymal stem cells (BMMSCs) have been found to enhance engraftment after hematopoietic stem cell transplantation. However, getting BMMSCs involves an invasive procedure. In this study, umbilical cord-derived mesenchymal stem cells (UCMSCs) were isolated from Wharton's jelly and cryopreserved in the UCMSCs bank. Compared with BMMSCs, we found that UCMSCs had superior proliferative potential. We found that NOD/SCID mice cotransplanted with CB and UCMSCs demonstrated significant human CD45 + cell engraftment compared with those transplanted with CB alone. Then, 20 patients with high-risk leukemia were prospectively randomized to either receive cotransplantation of CB and ex vivo expanded banked UCMSCs or to receive CBT alone. No serious adverse events were observed in the patients receiving UCMSC infusion. The time to undergo neutrophil engraftment and platelet engraftment was significantly shorter in the eight patients receiving cotransplantation than that in the 12 patients receiving CBT alone (p = 0.003 and p = 0.004, respectively). Thus, application of ex vivo expanded banked UCMSCs in humans appears to be feasible and safe. UCMSCs can enhance engraftment after CBT, but further studies are warranted.
INTRODUCTION
Mesenchymal stem cells (MSCs) can have clinical applications in regenerative medicine and tissue repair in adverse health events (9) such as heart diseases (14), neurological problems (13), lung diseases, liver diseases, renal diseases (5), diabetes, and bone problems. The immunomodulatory properties of MSCs make them clinically valuable in immune disorders (8, 15, 25, 31, 35) . In most previous reports, MSCs in human clinical applications were derived from bone marrow (BM) (4, 16, (18) (19) (20) (21) (22) 27, 29) . However, harvesting BM-derived MSCs (BMMSCs) involves an invasive and painful procedure. MSCs also can be isolated without an invasive procedure from fetal tissues, such as amniotic fluid (2), amniotic membrane (23), placenta, cord blood (CB) (5), and umbilical cord (UC) (12, 32) . The UC is rich with MSCs, and UC-derived MSCs (UCMSCs) have been shown to be easy to isolate and culture (32) . Therefore, the UC can be considered as an alternative source of MSCs for clinical applications.
Hematopoietic stem cell transplantation (HSCT) is an effective therapeutic modality for a variety of disorders. CB is a source of hematopoietic stem cells (HSCs), and there are some advantages in CB transplantation (CBT), including fast availability, tolerance of one to two human leukocyte antigen (HLA) mismatch, low incidence and severity of acute graft-versus-host disease (GVHD), low risk of transmitting infections, and lack of risks for donors (11) . However, because of the limited number of HSCs in CB, patients receiving CBT have been found to have delayed hematopoietic engraftment, which might result in more complications, such as infections and hemorrhage, and prolonged hospitalization (11, 30) .
Previous studies have documented that cotransplantation of HSCs and BMMSCs can enhance hematopoiesis, reduce the incidence of GVHD, accelerate lymphocyte recovery, and reduce the risk of graft failure (4, 16, 18, 21, 22, 27) . BMMSCs were also reported to promote hematopoietic engraftment after CBT (22) . Our previous studies found that no severe adverse effects were noted in patients receiving UCMSCs. We also found that UCMSCs could enhance engraftment after HSCT in patients with severe aplastic anemia and effectively treat severe acute GVHD (7, 34) . In the present study, after ex vivo and animal studies, we prospectively randomized subjects to investigate the safety and effect of cotransplantation of CB and UCMSCs in patients with high-risk leukemia.
PATIENTS AND METHODS

Isolation and Culture of BMMSCs
BM cells of healthy individuals were obtained from iliac crest aspirates. The institutional review board (IRB) of the China Medical University Hospital approved this protocol, and written informed consents were obtained. Mononuclear cells were isolated from BM aspirates by Ficoll-Paque density centrifugation (1.077 g/ml; Amersham Biosciences, Uppsala, Sweden) and then seeded in minimum essential medium with a modification (a-MEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen) and penicillin-streptomycin (Invitrogen). Cells were incubated at 37°C with 5% CO 2 in a humidified atmosphere. After 48 h, the medium with suspension of nonadherent cells was discarded, and fresh medium was added. Thereafter, the medium was replaced twice a week. When reaching 80-90% confluence, cells were detached with 0.25% trypsin-EDTA (Invitrogen) and replated at a concentration of 8.5 × 10 3 /cm 2 in 10-cm dishes.
Collection and Cryopreservation of UCMSCs
IRB approval and informed consent was obtained from all eligible UC donors who tested negative for human immunodeficiency virus (HIV)-I, HIV-II, human T-lymphotropic virus (HTLV)-I, HTLV-II, hepatitis B and C, cytomegalovirus (CMV), and syphilis and were free of any active infections during UCMSC harvesting. The UC was collected immediately after parturition and express-shipped to the UCMSC bank for MSC processing. UCMSCs were harvested from Wharton's jelly as previously described (7, 34) . Briefly, the main vessels were carefully removed, and the UC was sectioned to acquire Wharton's jelly. The jelly was digested using 1 mg/ml collagenase (Sigma, St. Louis, MO, USA) and plated in media (as above) at 5% CO 2 and 37°C in a humidified atmosphere. Forty-eight hours later, the suspended nonadherent cell-containing medium was discarded and replaced with fresh medium. The cells were detached with 0.25% trypsin-EDTA at 80-90% confluence and subcultured for further expansion. Once the cells had been proven negative for bacteria, fungi, mycoplasma, and endotoxins and UCMSCs were identified, the cells were cryopreserved in 10% dimethyl sulfoxide (DMSO; WAK-Chemie Medical GmbH, Steinbach, Germany) using a controlled-rate freezer and maintained in liquid nitrogen at the UCMSCs bank. All procedures for UCMSC processing complied with the current good tissue practice (GTP) requirements.
Identification of MSCs
BMMSCs and UCMSCs were immunolabeled with the following mouse anti-human antibodies: cluster of differentiation 14 (CD14), CD34, CD45, CD13, CD29, CD31, CD44, CD90, and HLA-DR (BD Biosciences, San Jose, CA, USA); CD105 (AbD Serotec, Oxford, UK); and CD73 (BD Pharmingen, San Diego, CA, USA). The cells were incubated with a secondary antibody, antimouse IgG-fluorescein isothiocyanate (FITC) or IgGphycoerythrin (PE) (BD Biosciences) and analyzed by flow cytometry (BD Biosciences). The MSCs then underwent osteogenic, adipogenic, and chondrogenic differentiation under specific induction conditions (6, 26) .
Proliferative Potential Assay
The population doublings of the cultured UCMSCs (n = 10) and BMMSCs (n = 10) were calculated according to the equation: population doubling = log 2 (the number of viable cells at harvest/the number of seeded cells) (6). The population doubling time was derived from the time interval divided by the cumulative population doubling from passages 2 to 6.
Cotransplantation of NOD/SCID Mice With CB and UCMSCs
The male nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice were obtained from the National Science Council (Taipei, Taiwan) and maintained at the Animal Center of China Medical University. There were two groups of 10 mice each (age 6-8 weeks) sublethally irradiated with 350 cGy (Varian, Palo Alto, CA, USA) and then transplanted with the following cells: (a) 10 6 total nucleated cells (TNCs) in the CB together with 10 6 UCMSCs and (b) 10 6 TNCs in the CB alone. The cells in these two groups were suspended in 250 ml of phosphate-buffered saline (Invitrogen) and injected into the lateral tail veins. These mice were sacrificed 6 weeks after transplantation. Peripheral blood samples were collected by cardiac puncture, and BM was harvested by flushing femurs and tibias with phosphate-buffered saline. To document hematopoietic cells engraftment, these cells from peripheral blood and BM were stained with a FITCconjugated antibody to human CD45 (BD Pharmingen), and the percentages of human CD45 + cells were measured by flow cytometry.
In addition, in order to compare the time of achieving complete chimerism between NOD/SCID mice cotransplanted with CB and UCMSCs and those transplanted with CB alone, we analyzed the percentages of human CD45 + cells in the peripheral blood collected from the tail vein every week in another two groups of 10 mice each (age 6-8 weeks) sublethally irradiated with 350 cGy and then transplanted. We defined the end point when complete chimerism (100% human CD45 + cells in peripheral blood) in mice was achieved.
Patients
After the IRB at the China Medical University Hospital and the Department of Health in Taiwan approved this study, children with high-risk leukemia but lacking HLA-matched siblings or unrelated donors were enrolled in this study at the China Medical University Hospital. The high-risk acute lymphoblastic leukemia (ALL) was defined as ALL with cytogenetic abnormalities indicating poor prognosis or in second remission. The high-risk acute myeloid leukemia (AML) was defined as AML with cytogenetic abnormalities indicating poor prognosis, in second remission, or with myelodysplastic syndrome. We prospectively randomized patients to receive cotransplantation of CB and UCMSCs or CBT alone. Parents or legal guardians of patients provided written informed consent for inclusion in this study. Written informed consent in accordance with the Declaration of Helsinki was also obtained from patients receiving UCMSC infusion by an independent physician to explain risks associated with UCMSC infusion. Patients who received CBT alone were enrolled as the control group.
Expansion, Thawing, and Infusion of UCMSCs
After we recruited suitable patients for the study (see Table 1 for demographics), we selected a unit of banked UCMSCs matching HLA based on antigen-level HLA-A, HLA-B, and HLA-DR typing with the recipients. UCMSC units and recipients should match at least three HLAs. The selected UCMSCs were thawed and subcultured in a-MEM supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere with 5% CO 2 . The medium was replaced twice a week. When reaching 80-90% confluence, cells were detached with 0.25% trypsin-EDTA and replated. When adequate cell dosages were obtained, the expanded UCMSCs were then cryopreserved again. After UCMSC expansion and before recryopreservation, karyotyping and screening for bacteria, fungi, mycoplasma, and endotoxins tests were performed. After the cells were shown to have a normal karyotype and were negative for infectious contamination, these cells were shipped from the UCMSC bank to our hospital. On the day of CBT, the UCMSCs were thawed, washed (16), and intravenously infused into the recipient through a central venous line, followed by CB infusion 4 h afterward. Some residual UCMSCs and suspension were tested again to rule out infectious contamination. All cotransplanted patients received one unit of CB and one unit of expanded UCMSCs. The collection, cryopreservation, expansion, thawing, and infusion of UCMSCs are summarized in Figure 1 .
Toxicity Assessment About UCMSCs
Vital signs were monitored at 15 and 30 min, 1, 2, 4, 6, 10, and 14 h after UCMSC infusion. Patients were monitored continuously for UCMSC infusion-related toxicities defined as alterations in vital organ functions, which cannot be explained by other intercurrent complications such as infection or chemoradiotherapy within 28 days of UCMSC infusion. To assess the presence of ectopic tissue formation, patients were evaluated by magnetic resonance imaging (MRI; GE Medical Systems, Milwaukee, WI, USA) and positron emission tomography (PET; GE Medical Systems) every 3 months after UCMSC infusion.
CB Selection
Searches for unrelated CB donors were processed through the CB bank approved by the Department of Health in Taiwan. The compatibility of HLA-A, -B, and -DRB1 was assessed by high-resolution typing. The CB units were selected according to the TNCs in the CB units and the HLA match between recipients and the CB units. The selected CB units had to contain at least 3 × 10 7 TNCs/ kg of the recipients (prethaw). A minimum of four HLA antigens shared with the recipients was required, and only one HLA-DRB1 single-locus mismatch was allowed. All patients enrolled in this study received one unit of CB, whether cotransplanted with UCMSCs or transplanted alone. Any patient receiving two or more units of CB was excluded.
Conditioning Regimens, GVHD Prophylaxis, and Supportive Care
Conditioning regimens were different according to ALL or AML. Patients with ALL received cyclophosphamide (Baxter Oncology GmbH, Halle, Germany) 60 mg/kg/day intravenously for 2 days, etoposide (Bristol-Myers Squibb, Princeton, NJ, USA) 30 mg/kg intravenously for 1 day, and total body irradiation 200 cGy twice a day for 3 days. Patients with AML were treated with intravenous busulfan (Otsuka, Tokyo, Japan) 1 mg/kg intravenously every 6 h for 4 days, and cyclophosphamide 60 mg/kg/day intravenously for 2 days. GVHD prevention consisted of intravenous or oral cyclosporine (Novartis, Basle, Switzerland) and intravenous methylprednisolone (Pfizer, NY, USA). All patients received rabbit thymoglobulin (Genzyme, Marcy 10 μg/kg/day) was administrated subcutaneously until absolute neutrophil count (ANC) > 1.0 × 10 9 /L. The ANC is calculated by multiplying the total leukocyte count by the percentage of segmented neutrophils and bands. Short tandem repeat analysis was used for assessment of engraftment after CBT (17). For short tandem repeat analysis, DNA was prepared from mononuclear cells obtained from the CB and peripheral blood of the recipient before CBT. Specific primers designed to flank repeated units of the apolipoprotein B (APO-B) and D1S80 gene regions were used for PCR amplification. Transplant-related mortality was defined as patients expired due to CBT.
Statistics
A boxplot was made to compare the human CD45 + cells between NOD/SCID mice cotransplanted with CB and UCMSCs and those transplanted with CB alone. A Mann-Whitney test and Fisher's exact probability test were used to assess differences between patients receiving cotransplantation of CB and UCMSCs and patients receiving CBT alone. The data are presented as median and range. A value of p < 0.05 was considered significant.
RESULTS
Comparisons Between UCMSCs and BMMSCs
UCMSCs showed the same uniform spindle-shaped morphology as BMMSCs, and they were both positive for CD13, CD29, CD44, CD73, CD90, and CD105 but negative for CD14, CD31, CD34, CD45, and HLA-DR. Under specific induction conditions, UCMSCs and BMMSCs possessed the capacity for adipogenic, osteogenic, and chondrogenic differentiation (6,26). A significant increase in cumulative population doubling from passages 2 to 6 was observed between UCMSCs (median, 6.3; range, 4.6-7.8) and BMMSCs (median, 2.9; range, 1.6-4.4) (p = 0.004). The population doubling time of UCMSCs (median, 1.4 days; range, 1.1-1.9 days) was significantly shorter than that of BMMSCs (median, 9.6 days; range, 11.7-7.2 days) (p = 0.003).
Comparisons Between NOD/SCID Mice Cotransplanted With CB and UCMSCs and Those Transplanted With CB Alone
As shown in Figure 2 , we found that NOD/SCID mice transplanted with 10 6 TNCs in the CB together with 10 6 UCMSCs demonstrated a significantly higher median 28.2% (range, 24.6-33.1%) number of human CD45 + cells engrafting in the peripheral blood than those transplanted with 10 6 TNCs in the CB alone (median, 5.3%; range, 4.2-6.5%; human CD45 + cell engraftment in the peripheral blood) (p = 0.001). NOD/SCID mice transplanted with 10 6 TNCs in the CB together with 10 6 UCMSCs demonstrated a significantly greater median 6.9% (range, 5.9-7.3%) number of human CD45 + cells engrafting in the BM than those transplanted with 10 6 TNCs in the CB alone (median, 1.7%; range, 1.5-2.3%; human CD45 + cell engraftment in the BM) (p = 0.015).
Of the 10 mice receiving cotransplantation of CB and UCMSCs, complete chimerism was observed after a median time of 9 weeks (range, 8-11 weeks). Of the 10 mice receiving CBT alone, complete chimerism was not observed until after a median time of 16 weeks (range, 14-20 weeks). By defining complete chimerism in mice as the end point, we found that faster engraftment was Figure 2 . Cotransplantation of umbilical cord-derived mesenchymal stem cells (UCMSCs) enhanced engraftment of human CD45 + cells in NOD/SCID mice. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice that were transplanted with cord blood (CB) together with 10 6 UCMSCs demonstrated a significantly higher human CD45 + cell engraftment in the peripheral blood and bone marrow compared to those transplanted with CB alone. achieved in mice receiving cotransplantion with CB and UCMSCs in comparison to those receiving CBT alone (p = 0.007). Based on the results of animal experimental investigation, we found that the cotransplantation of UCMSCs did enhance engraftment of CBT.
Characteristics of Patients and CB
The characteristics of eight patients with a median age of 9.8 years (range, 3.2-12.1 years) receiving cotransplantation of CB and UCMSCs are summarized in Table 1 . Of the 8 units of CB cotransplanted with UCMSCs, three CB donors were female, and five were male. Of the eight patients, three patients had ALL, and five patients had AML. Twelve patients with a median age of 8.5 years (range, 3.6-13.1 years) received CBT alone. Of these 12 patients, five patients had ALL, and seven patients had AML. The characteristics of the 12 patients are summarized in Table 2 . The age at transplant, gender, leukemia type, TNCs in CB, and CD34 cells in CB between patients receiving cotransplantation and those receiving CBT alone were not significantly different (Table 3) .
Characteristics of UCMSCs
Of the eight patients receiving cotransplantation of CB and UCMSCs, the range of HLA match between UCMSCs and recipients was 3/6 to 5/6. The median cell dose (×10 6 / kg) and passage of UCMSCs were 7.19 (range, 2.44-10.12) and 3 (range, 2-4), respectively. The median duration of expansion to sufficient UCMSCs was 7 days (range, 5-8 days). Of the 8 units of UCMSCs, five UCMSC donors were female, and three were male. UCMSCs infused to the eight patients were shown to have a normal karyotype and the absence of pathogenic contamination after ex vivo expansion. The characteristics of UCMSCs are summarized in Table 1 .
Safety of UCMSCs
The ex vivo expanded banked UCMSCs were infused during 30 min through a central venous line. The infusion of the UCMSCs was well tolerated by all recipients. There were no infusion-related toxicities such as allergic reactions, respiratory distress, or hypertensive responses. Of the eight patients receiving cotransplantation of CB and UCMSCs, no ectopic tissue was noted after MRI and PET survey in the interval of 3 months after UCMSC infusion. The median duration of follow-up after cotransplantation was 16.5 months (range, 8-27 months).
Engraftment, GVHD, and Outcome
All of the 20 patients, including the patients receiving cotransplantation and CBT only, achieved 100% donor chimerism assessed with the method of short tandem repeat on the 60th day after transplantation. Of the eight patients receiving cotransplantation of CB and UCMSCs, an ANC > 0.5 × 10 9 /L was seen after a median time of 12 days (range, 8-16 days) (Table 1) . Platelets count > 20 × 10 9 /L was achieved at a median time of 30 days (range, 20-45 days) (Table 1) after cotransplantation. Of the 12 patients receiving CBT alone, an ANC > 0.5 × 10 9 /L was seen after a median time of 21 days (range, 17-43 days). Platelet count > 20 × 10 9 /L was achieved at a median time of 73 days (range, 42-135 days) after CBT. Patients receiving cotransplantion had faster recovery of ANC (p = 0.003) and platelets (p = 0.004) in comparison to those receiving CBT alone (Table 3) .
None of the eight patients receiving cotransplantation encountered severe infection, including CMV disease, septic shock, or fungal infection. Of the eight patients receiving cotransplantation, four patients developed localized skin rashes (grades I-II acute GVHD), which responded to steroids. One of these four patients with acute GVHD developed limited chronic GVHD, which responded to long-term use of cyclosporine and steroids. Of the eight patients receiving cotransplantation, two patients expired due to leukemia relapse, and the other six patients remained alive and disease free with a median follow-up time of 16.5 months (range, 11-27 months). Of the 12 patients receiving CBT alone, one patient died from bacteremia due to Pseudomonas aeruginosa, one died from invasive pulmonary aspergillosis, and two patients died from leukemia relapse. The other eight patients remained alive and disease-free with a median follow-up time of 18.5 months (range, 12-31 months). The comparison between patients receiving cotransplantation and those receiving CBT alone is summarized in Table 3 .
DISCUSSION
In humans, BMMSCs are safe to infuse with no severe adverse events and no formation of ectopic tissue in clinical application (4, 16, (18) (19) (20) (21) (22) 27, 29) . However, all the experiences about MSC safety are from BMMSCs. Amariglio et al. reported that a donor-derived brain tumor following neural tissue that included neural stem cells derived from fetal tissue was transplanted in an ataxia telangiectasis patient with immune deficiency (1). UCMSCs, one kind of fetal tissue-derived MSCs, are more primitive than BMMSCs. Although fetal tissuederived MSCs are easier to obtain than BMMSCs and cause no suffering to the donor, the safety of these cells in human clinical application is still unknown but is likely to be very important. Few human clinical experiences of fetal tissue-derived MSCs have been reported until now (7, 12, 34) . In the present study, after we infused banked UCMSCs from third-party HLA-mismatched donors to patients who were severely immunocompromised in the course of CBT, there was no infusion toxicity and no ectopic tissues detected by MRI and PET after 8-27 months follow-up. Therefore, we speculate that UCMCSs may BMMSCs (19) . In the present study, after we infused 3/6 to 5/6 HLA-matched UCMSCs in the patients, no severe adverse effects were noted, and these cells enhanced hematopoiesis after CBT. Therefore, we speculate that the restriction of MSC matches between donors and recipients is less than other cells, such as HSCs. Besides, we found that UCMSCs proliferated faster than BMMSCs (34), as previously reported (3). In the present study, we could get an adequate cell dose of UCMSCs for recipients within 8 days, which is shorter than the time to get an adequate cell dose of BMMSCs for clinical use in the previous report (22) . Therefore, UC can be considered as an alternative source of MSCs for clinical applications.
Gong et al. reported on banking UCMSCs for clinical use (12). MSCs for human clinical use should not only be strictly qualified for cell quality but must also be infection free. Therefore, all procedures of clinical-grade MSCs should be managed in a qualified manner, such as under GTP conditions. However, not all physicians have the facilities to guarantee the quality of cells for clinical applications. In this study, all UCMSCs provided from the UCMSC bank under GTP conditions were free of contamination. Therefore, MSC banks that cryopreserve manufactured unrelated MSCs may help solve time, donor variability, and contamination problems. Like CB banks (28), MSC banks may have a ready supply of "offthe-shelf" cells available for clinical use.
Chemotherapy and/or radiotherapy prior to HSCT damages the marrow stroma (10). MSCs play an important role in providing the specialized BM microenvironment and secret cytokines for hematopoiesis (33). Additionally, MSCs (8, 15, 25, 31, 35) , including BMMSCs and UCMSCs, which we previously reported (34), possess immunosuppressive effects, so MSC infusion may suppress immune function in recipients and, therefore, enhance engraftment of donor HSCs. Cotransplantation of BMMSCs and HSCs was shown to promote engraftment after HSCT (4, 16, 18, 21, 22, 27) . In the present study, we found that patients receiving cotransplantation of CB and UCMSCs resulted in faster engraftment of ANC and platelets than those receiving CBT alone. Further studies are needed to confirm the cotransplantation of UCMSCs in the fast engraftment, the effect on GVHD, and long-term survival after CBT.
In conclusion, UCMSCs are easier to obtain without harm to the donor and proliferate faster than BMMSCs, which indicates that they may be ideal candidates for cellbased therapy. No severe adverse effects were noted in this human clinical application of UCMSCs. "Off-the-shelf" UCMSCs may make UCMSCs more available for clinical applications. Accordingly, application of ex vivo expanded banked UCMSCs in humans appears to be feasible and safe. Cotransplantation of UCMSCs was found to enhance hematopoiesis after CBT. Further studies are warranted.
